Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: A case-control study

Lancet

Volumn 354, Issue 9175, 1999, Pages 281-286

  Caparros Lefebvre, Dominique ^a   Elbaz, Alexis ^b  

^a Ctr Hosp Univ (CHU) Antilles G   (Puerto Rico)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT;

ADULT; AGED; ARTICLE; BRADYKINESIA; CARIBBEAN ISLANDS; DEMOGRAPHY; FEMALE; FRONTAL LOBE; FRUIT; GAIT DISORDER; GUADELOUPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEURON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TEA;

EID: 0033600443     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10166-6     Document Type: Article

References (36)

1. de Rick M.C., Tzourio C., Breteler M.M.et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of PD. J Neurol Neurosurg Psychiatry. 62:1997;10-15.
2. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr. 55:1992;181-184.
3. Golbe L.I., Davis P.H., Schoenberg B.S., Duvoisin R.C. Prevalence and natural history of progressive supranuclear palsy. Neurology. 38:1988;1031-1034.
4. Litvan L., Agid Y., Jankovic J.et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 46:1996;922-930.
5. Uitti R., Berry K., Yasuhara O.et al. Neurodegenerative "overlap" syndrome: clinical and pathological features of Parkinson's disease, motor neuron disease, and Alzheimer's disease. Parkinsonism Rel Disorders. 1:1995;21-34.
6. Elizan T.S., Hirano A., Abrams B.M. Amyotrophic lateral sclerosis and parkinsonism-dementia complex on Guam: neurological reevaluation. Arch Neurol. 14:1966;356-368.
7. Joseph H. Ethnopharmacognosie des annonacées de la Guadeloupe. Thèse de Pharmacie: Université de Montpellier I, 1983.
8. Leboeuf M., Legueut C., Cave A.et al. Alcoloïde des annonacées: alcaloïdes d'Annona muricata L.L. Planta Med. 42:1981;37-44.
9. Kotake Y., Yoshida M., Ogawa M.et al. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neurosci Lett. 217:1996;69-71.
10. Kawai H., Makino Y., Hirobe M., Ohta S. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivates: uptake by dopamine transporter and activity to induce parkinsonism. J Neurochem. 70:1998;745-751.
11. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 46:1996;1470.
12. Esteguy M., Bonnet A.M., Kefalos J., Lhermitte F., Agid Y. The L-dopa test in Parkinson's disease. Rev Neurol. 141:1985;413-415.
13. Fahn S, Elton RL, and members of the UPDRS development committee. Unified Parkinson's disease rating sale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease: vol II. Florham Park, New Jersey: Macmillan health information. 1987, 153-63.
14. Amarenco P., Roullet E., Hannoun L., Marteau R. Progressive supranuclear as the sole manifestation of systemic Whipple's disease treated with pefloxacine. J Neurol Neurosurg Psychiatr. 54:1991;1121-1122.
15. Litvan I., MacIntyre A., Goetz C.G.et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies. Arch Neurol. 55:1998;969-978.
16. Oyanagi K., Makifuchi T., Ohtoh T.et al. Amyotrophic lateral sclerosis of Guam: the nature of the neuropathologic findings. Acta Neuropathol. 88:1994;405-412.
17. Hof P.R., Nimchinsky E.A., Buée-Scherrer V.et al. Amyotrophic lateral sclerosis/parkinsomism dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability and comparison with related neurodegenerative disorders. Acta Neuropathol. 88:1994;397-404.
18. Rodgers-Johnson P., Garruto R.M.et al. Amyotrophic lateral sclerosis and parkinsonism dementia on Guam: a 30-year evaluation of clinical and neuropathologic trends. Neurology. 36:1986;7-13.
19. McGeer P.L., Schwab C., McGeer E.G., Haddock R.L., Steele J.C. Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Neurology. 49:1997;400-409.
20. Reed D., Labarthe D., Chen K.M., Stallones D. A cohort study of amyotrophic lateral sclerosis and parkinsonism dementia on Guam and Rota. Am J Epidemiol. 125:1987;92-100.
21. Elizan T.S., Hirano A., Abrams B.M. Amyotrophic lateral sclerosis and parkinsonism-dementia complex on Guam: neurological reevaluation. Arch Neurol. 14:1966;356-368.
22. Spencer P.S., Nunn P.B., Hugon J.et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science. 237:1987;517-522.
23. Hirano A., Malamud N., Kurland L.T. Parkinsonism-dementia complex, an endemic disease on the island of Guam, II: pathological features. Brain. 84:1961;662-679.
24. Hasrat J.A., Pieters L., DeBacker J.P., Vauquelin G., Vlietinck A.J. Screening of medicinal plants from Suriname for 5-HT1A ligands: bioactive isoquinoline alkaloids from the fruit of annona muricata. Phytomedicine. 4:1997;133-140.
25. Chaudhuri K.R., Richards M., Brooks D.J. Atypical parkinsonism in Afro-Caribbean and Asian population in the UK. Movement Disorders. 11(1):1996;534.
26. Booth R.G., Castagnoli N.J., Rollema H. Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives to MPTP/MPP+. Neurosci Lett. 100:1989;306-312.
27. Coleman T., Ellis S.W., Martin I.J., Lennard M.S., Tucker G.T. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther. 277:1996;685-690.
28. Martin R.O., Warren M.E., Rapoport H. The biosynthesis of opium alkaloids: reticuline as the benzyltetrahydroisoquinolin precursor of thebaine in biosynthesis with carbon-1-44 dioxide. Biochemistry. 6:1967;2355-2363.
29. Okada T., Shimada S., Sato K.et al. Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK 293 cells. Neurosci Res. 30:1998;87-90.
30. Cabedo N., Protais P., Cassels B.K., Cortes D. Synthesis and dopamine receptor selectivity of the benzyl-tetrahydroisoquinoline (R) (+) nor-roefractine. J Nat Prod. 61:1998;709-712.
31. Hasrat J.A., DeBruyne J., DeBacker J.P., Vauquelin G., Vlietinck A.J. Isoquinoline derivates isolated from the fruit of annona muricata as 5-HTergic 5-HT1A receptor agonist in rats: unexploited antidepressive (lead) products. J Pharm Pharmacol. 49:1997;1145-1149.
32. Bruneton J. Alcaloïdes dérivés de la phénylalanine et de la tyrosine. In: Technique et documentation. Pharmacognosie, phytochimie, plantes médicinale. Paris: Lavoisier, 1993: 707-27.
33. Kotake Y., Tasaki Y., Makino Y., Otha S., Hirobe M. 1-Benzyl 1-2-3-4 tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem. 65:1995;2633-2638.
34. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res. 29:1997;99-111.
35. Kovar J. Interaction of bovine glutamate dehydrogenase with isoquinoline alkaloids. Arch Biochem Biophys. 221:1983;271-288.
36. Wu Y.C., Liou Y.F., Lu S.T.et al. Cytotoxicity of isoquinoline alkaloids and their N-oxides. Planta Med. 55:1989;163-165.